Doris Hansen, MD

Articles

Outcomes and Factors for Consideration When Choosing Between CAR T Therapies

Surbhi Sidana, MD;Doris Hansen, MD;Melissa Alsina, MD;Leyla O. Shune, MD

June 30th 2025

Panelists discuss the real-world comparison of ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel) chimeric antigen receptor (CAR) T-cell therapies for multiple myeloma, highlighting cilta-cel’s superior efficacy but higher toxicity and emphasizing the importance of tailoring treatment decisions to individual patient factors such as disease stage, health status, and personal preferences.

Late-Line R/R: Treatment Landscape

Surbhi Sidana, MD;Doris Hansen, MD;Melissa Alsina, MD;Leyla O. Shune, MD

June 30th 2025

Panelists discuss the transformative impact of chimeric antigen receptor (CAR) T-cell therapy on treating relapsed/refractory multiple myeloma (R/R MM) in real-world settings, emphasizing improved patient outcomes, the expanding role of real-world evidence, and the nuanced decision-making required in selecting among newly approved, highly effective immunotherapies.

A panel of 4 experts on multiple myeloma

Future Perspectives on CAR T-Cell Therapy in Relapsed/Refractory MM

Saad Z. Usmani, MD, MBA, FACP;Rahul Banerjee, MD, FACP;Doris Hansen, MD;Yi Lin, MD, PhD

June 7th 2024

The panel concludes its discussion with key takeaways on the evolving role of CAR T-cell therapy in the treatment of patients with relapsed/refractory multiple myeloma.

Insights from CARTITUDE-4 and KarMMa-3 in R/R MM

Saad Z. Usmani, MD, MBA, FACP;Rahul Banerjee, MD, FACP;Doris Hansen, MD;Yi Lin, MD, PhD

May 31st 2024

Experts on multiple myeloma provide their impressions of the CARTITUDE-4 and KarMMa-3 studies, which led to the approval of cilta-cel and ide-cel in earlier lines of treatment for patients with relapsed/refractory disease.

CAR T-Cell Therapy in R/R MM: Treatment Selection, Safety, and Future Perspectives

Saad Z. Usmani, MD, MBA, FACP;Rahul Banerjee, MD, FACP;Doris Hansen, MD;Yi Lin, MD, PhD

May 31st 2024

Myeloma specialists have a comprehensive discussion on CAR T-cell therapy, highlighting treatment selection considerations, adverse event management strategies, unmet needs, and ongoing research.

Key Takeaways from the CARTITUDE-1 and KarMMa Studies

Saad Z. Usmani, MD, MBA, FACP;Rahul Banerjee, MD, FACP;Doris Hansen, MD;Yi Lin, MD, PhD

May 24th 2024

Focusing on later lines of therapy for patients with relapsed/refractory multiple myeloma, the panel provides key takeaways on the CARTITUDE-1 and KarMMa trials that investigated cilta-cel and ide-cel.

How CAR T-Cell Therapy Impacts Relapsed/Refractory MM Treatment

Saad Z. Usmani, MD, MBA, FACP;Rahul Banerjee, MD, FACP;Doris Hansen, MD;Yi Lin, MD, PhD

May 24th 2024

Yi Lin, MD, PhD, provides insights on the impact of CAR T-cell therapy on the evolving multiple myeloma treatment landscape.

The Impact of CAR T-Cell Therapy on Relapsed/Refractory MM Treatment

Saad Z. Usmani, MD, MBA, FACP;Rahul Banerjee, MD, FACP;Doris Hansen, MD;Yi Lin, MD, PhD

May 17th 2024

Rahul Banerjee, MD, FACP, discusses how the emergence of CAR T-cell therapy has impacted the multiple myeloma treatment landscape by addressing unmet needs and improving patients’ quality of life.

The Rationale for CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

Saad Z. Usmani, MD, MBA, FACP;Rahul Banerjee, MD, FACP;Doris Hansen, MD;Yi Lin, MD, PhD

May 17th 2024

A panel of experts on multiple myeloma discuss the rationale for CAR T-cell therapy, highlighting BCMA as a target and treatment administration practices.